SkinCure Oncology

Executive Summary

SkinCure Oncology is revolutionizing the treatment of non-melanoma skin cancer (NMSC) through its Image-Guided Superficial Radiotherapy (Image-Guided SRT) platform. Based in Boca Raton, Florida, the company offers a non-invasive, painless alternative to Mohs surgery, which is the current standard of care. Image-Guided SRT combines real-time imaging with precise radiation delivery, enabling dermatologists to treat NMSC lesions effectively while sparing healthy tissue. Founded in 2017, SkinCure Oncology targets the growing dermatology market, where the demand for non-surgical options is rising due to patient preference for better cosmetic outcomes and reduced recovery times. The company's solution addresses a key unmet need by providing an additional treatment modality within dermatology practices, potentially expanding the range of services offered and improving patient access. As a private entity, SkinCure Oncology's financials and operational milestones are not publicly disclosed; however, its focus on a proven technology (SRT) with image guidance suggests a differentiated approach in the competitive NMSC treatment landscape. The company's success will depend on adoption by dermatologists, clinical evidence supporting outcomes, and ability to navigate regulatory and reimbursement pathways.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with major dermatology group for practice adoption70% success
• TBDPublication of pivotal clinical study comparing Image-Guided SRT to Mohs surgery50% success
• Q1 2027Series B funding round to expand sales force and R&D60% success